Dataset opportunity
Wallabymedical — 医疗影像数据集机会
由 Wallabymedical 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
42.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2024 年为 16 亿美元，复合年增长率为 23.2%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（需审查个人身份信息）
Buyer persona
医疗人工智能与诊断影像公司
Wallabymedical 持有一个专有的医疗影像数据集，该数据集源自其在专利神经血管技术方面的研发。这一高质量的集合，以工业数据、医疗记录和监管证据为支撑，特别适合训练和验证诊断人工智能模型，尤其是在中风检测和动脉瘤分析等复杂的神经学应用中。
该数据是全球医疗影像人工智能市场的关键资产，该市场在 2024 年的价值为16 亿美元，预计将以23.2% 的复合年增长率增长。[1] 尽管由于高度监管的医疗数据（符合 HIPAA/GDPR）、临床试验共同所有权以及与专有研发的关联而存在访问复杂性，但该神经血管数据集的稀有性和特异性为开发下一代人工智能诊断工具提供了显著的竞争优势。[1] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：高度监管的医疗数据，需要符合 HIPAA/GDPR；临床试验数据所有权可能涉及医院合作伙伴；与专利神经血管技术相关联的专有研发数据 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Wallabymedical 拥有其自有临床验证的医疗设备产生的专有神经血管 影像数据集。这些数据对于训练高性能诊断人工智能模型至关重要，该市场目前的价值为 16 亿美元且正在快速增长。由于该数据集源自具有全球监管批准的设备，其价值得到了显著提升，这表明其质量、规模和地域多样性具有难以复制的独特组合。
See dimension details ↓- Buyer Demand90
高买家需求源于在复合年增长率为 23.2% 的医疗影像人工智能市场中竞争对高质量、专业化数据的迫切需求。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity90
占主导地位的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 个数据需求信号（3 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit42
⚠ 审查 — Wallaby Medical 的核心业务是开发和销售用于中风治疗的医疗设备，它还分销第三方人工智能影像软件，使其成为市场上的供应商，而不是休眠数据的来源。问题：公司核心业务是销售医疗设备（硬件），而不是作为副产品生成数据的服务。[3, 5, 7, 8]；公司积极销售/分销用于中风影像分析的人工智能软件作为其产品套件的一部分，这是一个智能产品。[2, 16]；在收购 Phenox GmbH（约 5 亿欧元）后，该公司拥有 700 多名员工和全球业务，几乎成为一家大型企业；该公司的隐私政策提到了收集使用数据，但这似乎是为了网站分析和改进服务，而不是一个独立的、专有的数据。
- Deep Qualification70
✓ 通过 — Wallaby Medical 是一家工具供应商，生产和销售神经血管设备。它通过广泛的研发和临床试验产生专有数据，但所有权可能与试验伙伴混合，并且数据受到高度监管。无法访问法律条款使得许可权不明确。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据证实了数据集源自已在主要全球市场获得监管批准的设备，为人工智能开发者提供了高质量的临床验证 影像数据，用于构建值得信赖的诊断工具。
Industrial data
这表明一项规模庞大且复杂的运营，拥有完整产品组合，表明该数据集不是一次性收集，而是可扩展的、持续的数据流，具有巨大的规模和多样性潜力。
Regulatory records
这证明了底层设备已在全球 60 多个国家/地区实现全球分销，确保生成的数据集能够反映来自美国、欧盟和亚洲等主要市场的多样化人群，这对于开发稳健且无偏见的人工智能模型至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Wallabymedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.6 billion in 2024, CAGR 23.2% (source: MarketsandMarkets Analysis). [1]. Investment score 42.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Maizex — 工业运营数据集机会
View opportunity →工业Alcemi — 工业传感器数据集机会
View opportunity →移动Eurorastpark — 移动遥测数据集机会
View opportunity →